Buyers With Considerable Losses Have Chance to Direct the Ocugen, Inc. Course Action Lawsuit

SAN DIEGO, July 14, 2021–(Business enterprise WIRE)–Robbins Geller Rudman & Dowd LLP announces that purchasers of Ocugen, Inc. (NASDAQ: OCGN) securities amongst February 2, 2021 and June 10, 2021, inclusive (the “Course Time period”) have right up until August 17, 2021 to find appointment as lead plaintiff in the Ocugen class motion lawsuit. The Ocugen course motion lawsuit (Nicanor v. Ocugen, Inc., No. 21-cv-02725) was commenced on July 17, 2021 in the Jap District of Pennsylvania and charges Ocugen and specified of its prime executives with violations of the Securities Trade Act of 1934.

If you suffered substantial losses and would like to serve as guide plaintiff of the Ocugen course motion lawsuit, please present your information by clicking here. You can also speak to lawyer J.C. Sanchez of Robbins Geller by calling 800/449-4900 or by using e-mail at [email protected]. Lead plaintiff motions for the Ocugen class action lawsuit ought to be submitted with the court docket no afterwards than August 17, 2021.

Situation ALLEGATIONS: The Ocugen class action lawsuit alleges that, all through the Course Time period, defendants created bogus and misleading statements and failed to disclose that: (i) the data that Ocugen submitted to the U.S. Food and Drug Administration (“Fda”) was insufficient to assistance an Unexpected emergency Use Authorization (“EUA”) (ii) Ocugen would not file an EUA with the Food and drug administration and (iii) as a end result, Ocugen’s fiscal statements, as very well as defendants’ statements about Ocugen’s business, operations, and prospective clients have been wrong and deceptive and/or lacked a reasonable foundation.

On June 10, 2021, Ocugen issued a push release saying that it would pursue a biologics license software (“BLA”) with the Food and drug administration rather of the previously introduced EUA. In carrying out so, Ocugen unveiled that “[t]he Fda presented feedback to Ocugen concerning the Master File the Organization experienced formerly submitted and advised that Ocugen go after a BLA submission alternatively of an EUA software for its vaccine applicant and asked for further info and info. Ocugen is in discussions with the Food and drug administration to have an understanding of the further info needed to guidance a BLA submission. The Company anticipates that data from an further medical demo will be expected to guidance the submission.” On this news, the value of Ocugen’s stock fell extra than 28%, damaging buyers.

THE Lead PLAINTIFF Approach: The Private Securities Litigation Reform Act of 1995 permits any investor who acquired Ocugen securities during the Course Period to seek appointment as direct plaintiff in the Ocugen class motion lawsuit. A direct plaintiff is normally the movant with the greatest fiscal curiosity in the relief sought by the putative class who is also typical and ample of the putative course. A lead plaintiff acts on behalf of all other class associates in directing the Ocugen course motion lawsuit. The direct plaintiff can select a regulation organization of its choice to litigate the Ocugen class action lawsuit. An investor’s ability to share in any prospective long term restoration of the Ocugen course motion lawsuit is not dependent upon serving as guide plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 lawyers in 9 offices nationwide, Robbins Geller Rudman & Dowd LLP is the major U.S. legislation business representing traders in securities class actions. Robbins Geller attorneys have acquired several of the most significant shareholder recoveries in record, which include the most significant securities class motion recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Action Providers Major 50 Report ranked Robbins Geller initially for recovering $1.6 billion for traders very last calendar year, more than double the amount recovered by any other securities plaintiffs’ company. Make sure you take a look at for more information and facts.

Attorney advertising and marketing.

Earlier benefits do not assure upcoming outcomes.

Products and services may well be done by attorneys in any of our places of work.

Check out resource variation on


Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
[email protected]